Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 5/20 | 0.67 |
| ▸ | ECE1 | P42892 | 8/20 | 0.57 |
| ▸ | MME | P08473 | 6/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.56 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20397780 | 0.88 | PIN1 (0.54) | PIN1ECE1MMECYP1A2AGTR2 | |
| SCHEMBL20397878 | 0.88 | PIN1 (0.54) | PIN1ECE1MMECYP1A2AGTR2 | |
| SCHEMBL20397877 | 0.88 | PIN1 (0.54) | PIN1ECE1MMECYP1A2AGTR2 | |
| SCHEMBL20397778 | 0.88 | PIN1 (0.54) | PIN1ECE1MMECYP1A2AGTR2 | |
| SCHEMBL18262700 | 0.84 | PIN1 (0.54) | PIN1ECE1MMEAGTR2NAALAD2 | |
| SCHEMBL13884234 | 0.84 | PIN1 (0.59) | PIN1ECE1MMECYP1A2AGTR2 | |
| SCHEMBL18262698 | 0.84 | PIN1 (0.54) | PIN1ECE1MMEAGTR2NAALAD2 | |
| SCHEMBL17007952 | 0.83 | PIN1 (0.49) | PIN1ECE1MMECYP1A2AGTR2 | |
| SCHEMBL20204233 | 0.82 | PIN1 (0.57) | PIN1ECE1MMEAGTR2 | |
| SCHEMBL16856563 | 0.82 | PIN1 (0.57) | PIN1ECE1MMEAGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154997-B9 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2021-04-14 | — | — | EP | disclosed |
| EP-3753578-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | Novartis AG (CH) | 2020-12-23 | — | — | EP | disclosed |
| US-10787480-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2020-09-29 | — | — | US | disclosed |
| EP-3154997-B1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2020-02-19 | — | — | EP | disclosed |
| EP-3082877-B1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2019-08-28 | — | — | EP | disclosed |
| US-10392421-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2019-08-27 | — | — | US | disclosed |
| US-20190194315-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2019-06-27 | — | — | US | disclosed |
| US-10280139-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2019-05-07 | — | — | US | disclosed |
| US-20180244717-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2018-08-30 | — | — | US | disclosed |
| US-20180155281-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2018-06-07 | — | — | US | disclosed |
| WO-2016203432-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| EP-3082877-A2 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | Novartis AG (CH) | 2016-10-26 | — | — | EP | disclosed |
| US-9278967-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-03-08 | — | — | US | disclosed |
| WO-2015189791-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015095301-A2 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | IRM LLC (BM) | 2015-06-25 | — | — | WO | disclosed |
| US-20150141643-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2015-05-21 | — | — | US | disclosed |
| EP-2433937-A1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2433936-A1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2433935-A1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787480-B2 | Cytotoxic peptides and conjugates thereof | CD47, NGLY1, VIP | PIN1 598/4885ECE1 540/4885MME 448/4885 |
| US-20190194315-A1 | ANTIBODY DRUG CONJUGATES | EPCAM, CDH1, VIM | PIN1 1956/4885ECE1 1810/4885MME 1613/4885 |
| US-10392421-B2 | Cytotoxic peptides and conjugates thereof | CD47, NGLY1, VIP | PIN1 598/4885ECE1 540/4885MME 448/4885 |
| US-20150141643-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | P2RX4, P2RX5, P2RX3 | PIN1 941/4885ECE1 3183/4885MME 2567/4885 |
| US-20180244717-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, NGLY1, VIP | PIN1 598/4885ECE1 540/4885MME 448/4885 |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, NGLY1, VIP | PIN1 598/4885ECE1 540/4885MME 448/4885 |
| US-20180155281-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, MKI67, NGLY1 | PIN1 772/4885ECE1 527/4885MME 420/4885 |
| US-10280139-B2 | Cytotoxic peptides and conjugates thereof | CD47, MKI67, NGLY1 | PIN1 772/4885ECE1 527/4885MME 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.